Literature DB >> 19838129

Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women.

Stewart E Reid1, James Y Dai, Jing Wang, Bupe N Sichalwe, Godspower Akpomiemie, Frances M Cowan, Sinead Delany-Moretlwe, Jared M Baeten, James P Hughes, Anna Wald, Connie Celum.   

Abstract

BACKGROUND: Biomedical HIV prevention trials enroll sexually active women at risk of HIV and often discontinue study product during pregnancy. We assessed risk factors for pregnancy and HIV acquisition, and the effect of pregnancy on time off study drug in HIV Prevention Trials Network 039.
METHODS: A total of 1358 HIV negative, herpes simplex virus type 2-seropositive women from South Africa, Zambia, and Zimbabwe were enrolled and followed for up to 18 months.
RESULTS: A total of 228 pregnancies occurred; time off study drug due to pregnancy accounted for 4% of woman-years of follow-up among women. Being pregnant was not associated with increased HIV risk (hazard ratio 0.64, 95% confidence interval 0.23-1.80, P = 0.40). However, younger age was associated with increased risk for both pregnancy and HIV. There was no association between condom use as a sole contraceptive and reduced pregnancy incidence; hormonal contraception was not associated with increased HIV risk. Bacterial vaginosis at study entry was associated with increased HIV risk (hazard ratio 2.03, P = 0.02).
CONCLUSIONS: Pregnancy resulted in only a small amount of woman-time off study drug. Young women are at high risk for HIV and are an appropriate population for HIV prevention trials but also have higher risk of pregnancy. Condom use was not associated with reduced incidence of pregnancy.

Entities:  

Mesh:

Year:  2010        PMID: 19838129      PMCID: PMC2845724          DOI: 10.1097/QAI.0b013e3181bc4869

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  14 in total

1.  Pregnancy in effectiveness trials of HIV prevention agents.

Authors:  Elizabeth G Raymond; Douglas Taylor; Willard Cates; Elizabeth E Tolley; David Borasky; Aida Cancel; Benoit Masse; Elizabeth A Bukusi; Brooke R Johnson
Journal:  Sex Transm Dis       Date:  2007-12       Impact factor: 2.830

Review 2.  Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies.

Authors:  Julius Atashili; Charles Poole; Peter M Ndumbe; Adaora A Adimora; Jennifer S Smith
Journal:  AIDS       Date:  2008-07-31       Impact factor: 4.177

3.  Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study.

Authors:  Ronald H Gray; Xianbin Li; Godfrey Kigozi; David Serwadda; Heena Brahmbhatt; Fred Wabwire-Mangen; Fred Nalugoda; Mohamed Kiddugavu; Nelson Sewankambo; Thomas C Quinn; Steven J Reynolds; Maria J Wawer
Journal:  Lancet       Date:  2005-10-01       Impact factor: 79.321

4.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

5.  Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  Stephanie Skoler-Karpoff; Gita Ramjee; Khatija Ahmed; Lydia Altini; Marlena Gehret Plagianos; Barbara Friedland; Sumen Govender; Alana De Kock; Nazira Cassim; Thesla Palanee; Gregory Dozier; Robin Maguire; Pekka Lahteenmaki
Journal:  Lancet       Date:  2008-12-06       Impact factor: 79.321

6.  Genital tract infections among HIV-infected pregnant women in Malawi, Tanzania and Zambia.

Authors:  S Aboud; G Msamanga; J S Read; A Mwatha; Y Q Chen; D Potter; M Valentine; U Sharma; I Hoffmann; T E Taha; R L Goldenberg; W W Fawzi
Journal:  Int J STD AIDS       Date:  2008-12       Impact factor: 1.359

7.  Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe.

Authors:  Charles S Morrison; Jing Wang; Barbara Van Der Pol; Nancy Padian; Robert A Salata; Barbra A Richardson
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

8.  Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.

Authors:  Connie Celum; Anna Wald; James Hughes; Jorge Sanchez; Stewart Reid; Sinead Delany-Moretlwe; Frances Cowan; Martin Casapia; Abner Ortiz; Jonathan Fuchs; Susan Buchbinder; Beryl Koblin; Sheryl Zwerski; Scott Rose; Jing Wang; Lawrence Corey
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

Review 9.  The influence of hormonal contraceptive use on HIV-1 transmission and disease progression.

Authors:  Jared M Baeten; Ludo Lavreys; Julie Overbaugh
Journal:  Clin Infect Dis       Date:  2007-06-18       Impact factor: 9.079

10.  Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women.

Authors:  Jared M Baeten; Sarah Benki; Vrasha Chohan; Ludo Lavreys; R Scott McClelland; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Walter Jaoko; Julie Overbaugh
Journal:  AIDS       Date:  2007-08-20       Impact factor: 4.177

View more
  59 in total

1.  Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial.

Authors:  Sengeziwe Sibeko; Cheryl Baxter; Nonhlanhla Yende; Quarraisha Abdool Karim; Salim S Abdool Karim
Journal:  Obstet Gynecol       Date:  2011-10       Impact factor: 7.661

2.  In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women.

Authors:  Brenna L Anderson; Mimi Ghosh; Christina Raker; John Fahey; Yan Song; Dwight J Rouse; Charles R Wira; Susan Cu-Uvin
Journal:  Am J Obstet Gynecol       Date:  2012-04-30       Impact factor: 8.661

3.  The impact of pregnancy on anti-HIV activity of cervicovaginal secretions.

Authors:  Brenna L Hughes; Riana Dutt; Christina Raker; Melody Barthelemy; Richard M Rossoll; Bharat Ramratnam; Charles R Wira; Susan Cu-Uvin
Journal:  Am J Obstet Gynecol       Date:  2016-07-05       Impact factor: 8.661

4.  Contraceptive Preference Among Women at Risk of HIV Acquisition in a Preparatory Screening Study for a Phase III Microbicide Trial in South Western Uganda.

Authors:  Sylvia Kusemererwa; Andrew Abaasa; Martin Onyango; Annalene M Nel; Michelle Isaacs; Gershim Asiki
Journal:  AIDS Behav       Date:  2018-07

Review 5.  Clinical parameters essential to methodology and interpretation of mucosal responses.

Authors:  Brenna L Anderson; Susan Cu-Uvin
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

6.  Maximizing the impact of HIV prevention efforts: interventions for couples.

Authors:  Amy Medley; Rachel Baggaley; Pamela Bachanas; Myron Cohen; Nathan Shaffer; Ying-Ru Lo
Journal:  AIDS Care       Date:  2013-05-08

7.  Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition.

Authors:  Richard M Novak; Barbara Metch; Susan Buchbinder; Robinson Cabello; Yeycy Donastorg; John-Peter Figoroa; Hend Abdul-Jauwad; Hend Adbul-Jauwad; Patrice Joseph; Ellen Koenig; David Metzger; Magda Sobieszycz; Mark Tyndall; Carmen Zorilla
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

Review 8.  Sustained High HIV Incidence in Young Women in Southern Africa: Social, Behavioral, and Structural Factors and Emerging Intervention Approaches.

Authors:  Abigail Harrison; Christopher J Colvin; Caroline Kuo; Alison Swartz; Mark Lurie
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

9.  Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial.

Authors:  Carolyne A Akello; Katherine E Bunge; Clemensia Nakabiito; Brenda G Mirembe; Mary Glenn Fowler; Anupam Mishra; Jeanne Marrazzo; Zvavahera M Chirenje; Connie Celum; Jennifer E Balkus
Journal:  J Womens Health (Larchmt)       Date:  2017-02-17       Impact factor: 2.681

10.  Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals?

Authors:  Chelsea B Polis; Sharon J Phillips; Sharon L Hillier; Sharon L Achilles
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.